{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:25:18Z","timestamp":1769063118746,"version":"3.49.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"publisher","award":["EMA\/2021\/17\/TDA"],"award-info":[{"award-number":["EMA\/2021\/17\/TDA"]}],"id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1053\/j.seminhematol.2022.03.001","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T01:58:33Z","timestamp":1646618313000},"page":"108-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Longitudinal Aspects of VITT"],"prefix":"10.1053","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6660-9949","authenticated-orcid":false,"given":"Linda","family":"Sch\u00f6nborn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Greinacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2022.03.001_bib0001","unstructured":"World Health Organization. Report of the independent allocation of vaccines group on the allocation of COVAX facility secured vaccines. https:\/\/www.who.int\/publications\/m\/item\/report-of-the-independent-allocation-of-vaccines-group-on-the-allocation-of-covax-facility-secured-vaccines-29-july-2021 [accessed September 09, 2021]."},{"key":"10.1053\/j.seminhematol.2022.03.001_bib0002","unstructured":"WHO. COVID-19 vaccine tracker and landscape. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines. [accessed September 13, 2021]."},{"key":"10.1053\/j.seminhematol.2022.03.001_bib0003","unstructured":"Paul-Ehrlich-Institut. Sicherheitsbericht. https:\/\/www.pei.de\/SharedDocs\/Downloads\/DE\/newsroom\/dossiers\/sicherheitsberichte\/sicherheitsbericht-27-12-bis-30-06-21.pdf?__blob=publicationFile&v=5. [accessed July 18, 2021]."},{"key":"10.1053\/j.seminhematol.2022.03.001_bib0004","unstructured":"Government United Kingdom. Coronavirus vaccine - weekly summary of Yellow Card reporting. https:\/\/www.gov.uk\/government\/publications\/coronavirus-covid-19-vaccine-adverse-reactions\/coronavirus-vaccine-summary-of-yellow-card-reporting [accessed July 18, 2021]."},{"key":"10.1053\/j.seminhematol.2022.03.001_bib0005","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical features of vaccine-induced immune thrombocytopenia and thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1053\/j.seminhematol.2022.03.001_bib0006","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1056\/NEJMc2105869","article-title":"Thrombotic thrombocytopenia after Ad26.COV2.S vaccination","volume":"384","author":"Muir","year":"2021","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1053\/j.seminhematol.2022.03.001_bib0007","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1001\/jama.2021.7517","article-title":"US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021","volume":"325","author":"See","year":"2021","journal-title":"JAMA"},{"issue":"22","key":"10.1053\/j.seminhematol.2022.03.001_bib0008","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1053\/j.seminhematol.2022.03.001_bib0009","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1053\/j.seminhematol.2022.03.001_bib0010","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2022.03.001_bib0011","doi-asserted-by":"crossref","unstructured":"Thiele T, Weisser K, Sch\u00f6nborn L, et al. Laboratory confirmed vaccine-induced immune thrombotic thrombocytopenia: Retrospective analysis of reported cases after vaccination with ChAdOx-1 nCoV-19 in Germany. The Lancet Regional Health - Europe. 2022;12:100270.","DOI":"10.1016\/j.lanepe.2021.100270"},{"issue":"18","key":"10.1053\/j.seminhematol.2022.03.001_bib0012","doi-asserted-by":"crossref","first-page":"680","DOI":"10.15585\/mmwr.mm7018e2","article-title":"Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine - United States, March-April 2021","volume":"70","author":"Shay","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"10.1053\/j.seminhematol.2022.03.001_bib0013","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.3324\/haematol.2021.279000","article-title":"Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia","volume":"106","author":"Althaus","year":"2021","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2022.03.001_bib0014","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1056\/NEJMc2106383","article-title":"PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia","volume":"385","author":"Vayne","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2022.03.001_bib0015","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-021-03744-4","article-title":"Antibody epitopes in vaccine-induced immune thrombotic thrombocytopenia","volume":"596","author":"Huynh","year":"2021","journal-title":"Nature"},{"issue":"11","key":"10.1053\/j.seminhematol.2022.03.001_bib0016","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1111\/jth.13813","article-title":"Autoimmune heparin-induced thrombocytopenia","volume":"15","author":"Greinacher","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2022.03.001_bib0017","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.thromres.2021.05.018","article-title":"Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia","volume":"204","author":"Warkentin","year":"2021","journal-title":"Thromb Res"},{"issue":"19","key":"10.1053\/j.seminhematol.2022.03.001_bib0018","first-page":"1883","article-title":"Heparin-induced thrombocytopenia","volume":"373","author":"Greinacher","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1053\/j.seminhematol.2022.03.001_bib0019","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1056\/NEJM200104263441704","article-title":"Temporal aspects of heparin-induced thrombocytopenia","volume":"344","author":"Warkentin","year":"2001","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1053\/j.seminhematol.2022.03.001_bib0020","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1182\/blood-2008-08-173062","article-title":"The temporal profile of the anti-PF4\/heparin immune response","volume":"113","author":"Greinacher","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1053\/j.seminhematol.2022.03.001_bib0021","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2021013231","article-title":"Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia","volume":"138","author":"Greinacher","year":"2021","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2022.03.001_bib0022","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1056\/NEJMc2112760","article-title":"Decline in pathogenic antibodies over time in VITT","volume":"385","author":"Sch\u00f6nborn","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2022.03.001_bib0023","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021014214","article-title":"Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient","author":"Sch\u00f6nborn","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2022.03.001_bib0024","doi-asserted-by":"crossref","first-page":"n1088","DOI":"10.1136\/bmj.n1088","article-title":"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study","volume":"373","author":"Lopez Bernal","year":"2021","journal-title":"BMJ"},{"issue":"10295","key":"10.1053\/j.seminhematol.2022.03.001_bib0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(21)01420-3","article-title":"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"398","author":"Borobia","year":"2021","journal-title":"Lancet"},{"issue":"38","key":"10.1053\/j.seminhematol.2022.03.001_bib0026","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.15585\/mmwr.mm7038e1","article-title":"Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions - United States, March-August 2021","volume":"70","author":"Self","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1053\/j.seminhematol.2022.03.001_bib0027","unstructured":"COVID-19 Vaccine Booster Shots https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/booster-shot.html: National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases; 2021 [accessed December 17, 2021]."},{"issue":"9","key":"10.1053\/j.seminhematol.2022.03.001_bib0028","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1182\/blood-2018-05-850370","article-title":"Fibronectin modulates formation of PF4\/heparin complexes and is a potential factor for reducing risk of developing HIT","volume":"133","author":"Krauel","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2022.03.001_bib0029","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1378\/chest.10-1599","article-title":"Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE","volume":"140","author":"Warkentin","year":"2011","journal-title":"Chest"},{"issue":"5","key":"10.1053\/j.seminhematol.2022.03.001_bib0030","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1600-0609.2005.00621.x","article-title":"Incidence and clinical significance of anti-PF4\/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia","volume":"76","author":"Juhl","year":"2006","journal-title":"Eur J Haematol"},{"issue":"8","key":"10.1053\/j.seminhematol.2022.03.001_bib0031","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/jth.15362","article-title":"Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination","volume":"19","author":"Platton","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2022.03.001_bib0032","doi-asserted-by":"crossref","unstructured":"Nicolson PLR, Montague SJ, Smith CW, et al. Anti-PF4 levels of patients with VITT do not reduce 4 months following AZD1222 vaccination. medRxiv. 2021:2021.08.17.21262138.","DOI":"10.1101\/2021.08.17.21262138"},{"issue":"4","key":"10.1053\/j.seminhematol.2022.03.001_bib0033","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1172\/JCI106279","article-title":"Metabolic properties of IgG subclasses in man","volume":"49","author":"Morell","year":"1970","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2022.03.001_bib0034","doi-asserted-by":"crossref","first-page":"e245092","DOI":"10.1136\/bcr-2021-245092","article-title":"Rare case of COVID-19 vaccine-associated intracranial haemorrhage with venous sinus thrombosis","volume":"14","author":"Purkayastha","year":"2021","journal-title":"BMJ Case Rep CP"},{"issue":"9","key":"10.1053\/j.seminhematol.2022.03.001_bib0035","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1056\/NEJMc2109465","article-title":"Therapeutic plasma exchange in vaccine-induced immune thrombotic thrombocytopenia","volume":"385","author":"Patriquin","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2022.03.001_bib0036","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood-2010-08-301424","article-title":"Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia","volume":"117","author":"Krauel","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2022.03.001_bib0037","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.str.2011.03.023","article-title":"Insights into the evolution of a complex virus from the crystal structure of vaccinia virus D13","volume":"19","author":"Bahar","year":"2011","journal-title":"Structure"},{"key":"10.1053\/j.seminhematol.2022.03.001_bib0038","doi-asserted-by":"crossref","unstructured":"Baker AT, Boyd RJ, Sarkar D, et al. The structure of ChAdOx1\/AZD-1222 reveals interactions with CAR and PF4 with implications for vaccine-induced immune thrombotic thrombocytopenia. bioRxiv. 2021:2021.05.19.444882.","DOI":"10.1101\/2021.05.19.444882"},{"key":"10.1053\/j.seminhematol.2022.03.001_sbref0039","article-title":"Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines","author":"Michalik","year":"2022","journal-title":"only epub ahead of print available Haematologica"},{"issue":"6","key":"10.1053\/j.seminhematol.2022.03.001_bib0040","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1182\/blood-2013-11-540781","article-title":"B-cell tolerance regulates production of antibodies causing heparin-induced thrombocytopenia","volume":"123","author":"Zheng","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2022.03.001_bib0041","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nri3383","article-title":"Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes","volume":"13","author":"Cerutti","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1053\/j.seminhematol.2022.03.001_bib0042","first-page":"813","article-title":"Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia","volume":"116","author":"Warkentin","year":"2016","journal-title":"Thromb Haemost"},{"issue":"22","key":"10.1053\/j.seminhematol.2022.03.001_bib0043","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMc2112974","article-title":"Vaccine-induced thrombocytopenia with severe headache","volume":"385","author":"Salih","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2022.03.001_bib0044","doi-asserted-by":"crossref","first-page":"e12578","DOI":"10.1002\/rth2.12578","article-title":"Vaccine-induced immune thrombotic thrombocytopenia following AstraZeneca (ChAdOx1 nCOV19) vaccine-A case report","volume":"5","author":"Al Rawahi","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"11","key":"10.1053\/j.seminhematol.2022.03.001_bib0045","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.3324\/haematol.2021.279246","article-title":"Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia","volume":"106","author":"Bonato","year":"2021","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2022.03.001_bib0046","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.thromres.2021.09.017","article-title":"Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia","volume":"207","author":"Thaler","year":"2021","journal-title":"Thromb Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2022.03.001_bib0047","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12959-021-00317-3","article-title":"Successful venous thromboprophylaxis in a patient with vaccine-induced immune thrombotic thrombocytopenia (VITT): a case report of the first reported case in Thailand","volume":"19","author":"Khuhapinant","year":"2021","journal-title":"Thromb J"},{"issue":"9","key":"10.1053\/j.seminhematol.2022.03.001_bib0048","doi-asserted-by":"crossref","first-page":"E346","DOI":"10.1002\/ajh.26265","article-title":"Vaccine-induced thrombotic thrombocytopenia following Ad26.COV2.S vaccine in a man presenting as acute venous thromboembolism","volume":"96","author":"Abou-Ismail","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2022.03.001_bib0049","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.thromres.2021.10.008","article-title":"Clinical course, management, and platelet activity assessment of splanchnic VITT: a case report","volume":"208","author":"Corica","year":"2021","journal-title":"Thromb Res"},{"issue":"11","key":"10.1053\/j.seminhematol.2022.03.001_bib0050","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.3390\/vaccines9111344","article-title":"Complicated long term vaccine induced thrombotic immune thrombocytopenia-a case report","volume":"9","author":"Gunther","year":"2021","journal-title":"Vaccines"},{"key":"10.1053\/j.seminhematol.2022.03.001_bib0051","doi-asserted-by":"crossref","first-page":"n2195","DOI":"10.1136\/bmj.n2195","article-title":"Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance","volume":"375","author":"Pavord","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"10.1053\/j.seminhematol.2022.03.001_bib0052","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1055\/a-1469-7481","article-title":"Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH","volume":"41","author":"Oldenburg","year":"2021","journal-title":"Hamostaseologie"},{"issue":"1","key":"10.1053\/j.seminhematol.2022.03.001_bib0053","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/jth.15572","article-title":"Vaccine-induced immune thrombotic thrombocytopenia (VITT): update on diagnosis and management considering different resources","volume":"20","author":"Greinacher","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1053\/j.seminhematol.2022.03.001_bib0054","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1055\/a-1481-3039","article-title":"Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): targeting pathomechanisms with bruton tyrosine kinase inhibitors","volume":"121","author":"von Hundelshausen","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2022.03.001_bib0055","doi-asserted-by":"crossref","unstructured":"Smith CW, Kardeby C, Di Y, et al. Platelet activation by Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) patient serum is blocked by COX, P2Y12and kinase inhibitors. medRxiv. 2021:2021.04.24.21255655.","DOI":"10.1101\/2021.04.24.21255655"},{"key":"10.1053\/j.seminhematol.2022.03.001_bib0056","unstructured":"NICE. COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT): the National Institute for Health and Care Excellence (NICE); 2021 [accessed December 08, 2021]. Available from: https:\/\/www.nice.org.uk\/guidance\/ng200\/resources\/covid19-rapid-guideline-vaccineinduced-immune-thrombocytopenia-and-thrombosis-vitt-pdf-51036811744."},{"key":"10.1053\/j.seminhematol.2022.03.001_bib0057","first-page":"1","article-title":"Vaccine-induced immune thrombocytopenia and thrombosis: The decline in anti-platelet factor 4 antibodies is assay-dependent","volume":"00","author":"Platton","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2022.03.001_bib0058","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s10194-021-01324-5","article-title":"Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis","volume":"22","author":"Garcia-Azorin","year":"2021","journal-title":"J Headache Pain"},{"issue":"22","key":"10.1053\/j.seminhematol.2022.03.001_bib0059","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1182\/bloodadvances.2021005388","article-title":"VITT following Ad26.COV2.S vaccination presenting without radiographically demonstrable thrombosis","volume":"5","author":"Kennedy","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"10.1053\/j.seminhematol.2022.03.001_bib0060","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1055\/a-1701-2926","article-title":"Heterogeneity of vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination and safety of second vaccination with BNT162b2","volume":"122","author":"Lindhoff-Last","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2022.03.001_bib0061","article-title":"VITT and second doses of Covid-19 vaccine","author":"Lacy","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1053\/j.seminhematol.2022.03.001_bib0062","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1182\/blood-2013-10-533083","article-title":"Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin","volume":"123","author":"Warkentin","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2022.03.001_bib0063","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/jth.15633","article-title":"The COVID-19 vaccine ChAdOx1-S is not contaminated with sulfated glycosaminoglycans","volume":"20","author":"Alban","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1053\/j.seminhematol.2022.03.001_bib0064","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/jth.15604","article-title":"Thrombosis and thrombocytopenia after HPV vaccination","volume":"20","author":"Johansen","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"14","key":"10.1053\/j.seminhematol.2022.03.001_bib0065","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood.2021012938","article-title":"Anti\u2013platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein","volume":"138","author":"Greinacher","year":"2021","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196322000105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196322000105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:28:12Z","timestamp":1758522492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196322000105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0037196322000105"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2022.03.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal Aspects of VITT","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2022.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}